Novo Nordisk Shares Fall
Digest more
The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes ...
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
On the face of it, the chances of success appear slim: the vast majority of experimental drugs for Alzheimer’s have ended in ...
The downturn at Novo Nordisk A/S could deal a further blow to Danish consumer confidence, with the drugmaker’s slumping ...
Yesterday, the U.S. Court of Appeals for the Third Circuit nixed the latest challenge filed by a major pharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback